BIODESIX INC (BDSX) Stock Price & Overview
NASDAQ:BDSX • US09075X2071
Current stock price
The current stock price of BDSX is 17.88 USD. Today BDSX is down by -6.63%. In the past month the price increased by 65.02%. In the past year, price increased by 23.81%.
BDSX Key Statistics
- Market Cap
- 176.297M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.85
- Dividend Yield
- N/A
BDSX Stock Performance
BDSX Stock Chart
BDSX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to BDSX. When comparing the yearly performance of all stocks, BDSX is one of the better performing stocks in the market, outperforming 95.66% of all stocks.
BDSX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BDSX. Both the profitability and financial health of BDSX have multiple concerns.
BDSX Earnings
On February 26, 2026 BDSX reported an EPS of -0.49 and a revenue of 25.15M. The company beat EPS expectations (43.81% surprise) and missed revenue expectations (-4.17% surprise).
BDSX Forecast & Estimates
11 analysts have analysed BDSX and the average price target is 33.15 USD. This implies a price increase of 85.4% is expected in the next year compared to the current price of 17.88.
For the next year, analysts expect an EPS growth of 30.6% and a revenue growth 25.44% for BDSX
BDSX Groups
Sector & Classification
BDSX Financial Highlights
Over the last trailing twelve months BDSX reported a non-GAAP Earnings per Share(EPS) of -4.85. The EPS increased by 30.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.31% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BDSX Ownership
BDSX Latest News, Press Relases and Analysis
BDSX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 10.5 | 96.777B | ||
| CI | THE CIGNA GROUP | 8.55 | 70.049B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 92.56 | 25.127B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.59 | 22.071B | ||
| LH | LABCORP HOLDINGS INC | 14.65 | 21.795B | ||
| GH | GUARDANT HEALTH INC | N/A | 10.825B | ||
| DVA | DAVITA INC | 10.66 | 10.224B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 27.62 | 7.478B | ||
| CHE | CHEMED CORP | 16.57 | 5.502B | ||
| HIMS | HIMS & HERS HEALTH INC | 45.36 | 5.434B | ||
| RDNT | RADNET INC | 78.04 | 4.626B | ||
| OPCH | OPTION CARE HEALTH INC | 15.36 | 4.598B | ||
| HNGE | HINGE HEALTH INC-A | 23.31 | 3.5B |
Related stock screener links
View all stocks in the Health Care Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BDSX
Company Profile
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Louisville, Colorado and currently employs 334 full-time employees. The company went IPO on 2020-10-28. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
Company Info
IPO: 2020-10-28
BIODESIX INC
919 West Dillon Road
Louisville COLORADO US
Employees: 273
Phone: 13034170500
BIODESIX INC / BDSX FAQ
Can you describe the business of BIODESIX INC?
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Louisville, Colorado and currently employs 334 full-time employees. The company went IPO on 2020-10-28. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
What is the stock price of BIODESIX INC today?
The current stock price of BDSX is 17.88 USD. The price decreased by -6.63% in the last trading session.
What is the dividend status of BIODESIX INC?
BDSX does not pay a dividend.
What is the ChartMill technical and fundamental rating of BDSX stock?
BDSX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is BIODESIX INC (BDSX) stock traded?
BDSX stock is listed on the Nasdaq exchange.
How is the market expecting BDSX stock to perform?
11 analysts have analysed BDSX and the average price target is 33.15 USD. This implies a price increase of 85.4% is expected in the next year compared to the current price of 17.88.
How many employees does BIODESIX INC have?
BIODESIX INC (BDSX) currently has 273 employees.